The ceramide system as a novel antidepressant target

Trends Pharmacol Sci. 2014 Jun;35(6):293-304. doi: 10.1016/j.tips.2014.04.003. Epub 2014 May 1.

Abstract

Major depression is a systems disorder which impairs not only central nervous system aspects of mood and behavior but also peripheral organ systems. Current views on the pathogenesis and treatment of depression are predominantly based on proteins and transmitters and thus are difficult to reconcile central with peripheral pathomechanisms. Recent research showed that there is also a lipid-based pathway involved in the pathology of depression, which is activated by psychosocial stress, oxidative stress, or inflammation. Inducible dysfunction of the ceramide pathway, which is abundant in the brain as well as in peripheral organs, may account for mood disorder, behavioral symptoms, and further promote inflammation and oxidative stress in peripheral systems. As such, the lipid ceramide pathway may provide the missing link between brain dysfunction and somatic symptoms of depression. Pharmacological interventions that reduce ceramide abundance also show antidepressant action and may promise a better treatment of major depression.

Keywords: acid sphingomyelinase; ceramide; depression; inflammation; neurogenesis; stress.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antidepressive Agents / pharmacokinetics
  • Antidepressive Agents / pharmacology*
  • Brain / drug effects
  • Brain / metabolism
  • Ceramides / metabolism*
  • Humans
  • Molecular Targeted Therapy

Substances

  • Antidepressive Agents
  • Ceramides